Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03514901
Other study ID # BeyPro2
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 18, 2018
Est. completion date April 29, 2023

Study information

Verified date December 2021
Source Intergruppo Melanoma Italiano
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib.


Description:

Melanoma is a heterogeneous skin tumor, characterized by mutations of different oncogenes. Almost half of patients with advanced melanoma have a gene mutation of BRAF serine-threonine kinase. Over the past 5 years, two BRAF inhibitors targeting these mutations, vemurafenib and dabrafenib, have shown high rates of rapid response in phase II and III studies. However, the duration of responses is limited in most patients due to the development of acquired resistance. Mechanisms of resistance to BRAF inhibitor therapy are diverse and include the reactivation of the mitogen-activated protein kinase (MAPK) pathway in over two-thirds of tumors, along with promotion of parallel signaling networks. Recently, the combination of drugs was superior in terms of responses, Progression Free Survival (PFS) and Overall Survival (OS) compared to monotherapy. The data from recent studies confirm the clinical benefit of the combination of Vemurafenib with cobimetinib and support the use of the combination as a standard first-line approach to improve survival in patients. The aim of this randomized, open-label, phase II study is to evaluate the efficacy, in terms of overall survival, of vemurafenib combined with cobimetinib associated with local treatment compared with second-line therapy, in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date April 29, 2023
Est. primary completion date April 29, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with histologically confirmed melanoma, either unresectable Stage IIIc or Stage IV metastatic melanoma, as defined by the American Joint Committee on Cancer 7th edition - Patients previously untreated for metastatic melanoma - Documentation of BRAFV600 mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples) by a validated mutational test - Adequate performance status to receive vemurafenib and cobimetinib therapy as determined by treating physician - Male or female patient aged =18 years - Able to participate and willing to give written informed consent prior to any treatment-related procedures and to comply with treatment guidance - Adequate end-organ function, defined by the following laboratory results obtained within 14 days prior to the first dose of program drug treatment: 1. Bilirubin = 1.5 x the upper limit of normal (ULN). 2. AST, ALT, and alkaline phosphatase = 3 x ULN, with the following exceptions: - Patients with documented liver metastases: AST and/or ALT = 5 x ULN. - Patients with documented liver or bone metastases: alkaline phosphatase = 5 x ULN. 3. Serum creatinine =1.5 x ULN or creatinine clearance (CrCl) = 40 mL/min based on measured CrCl from a 24-hour urine collection or Cockroft-Gault glomerular filtration rate estimation. - Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use two effective forms of contraception during program therapy and for at least 6 months after completion of program therapy - Negative serum pregnancy test prior to commencement of dosing in women of childbearing potential - Patient should be able to swallow tablets - Absence of any psychological, familial, sociological, or geographical condition that potentially hampers compliance with the treatment regimen - Patient does not currently participate in other clinical trials Exclusion Criteria: - Palliative radiotherapy within 7 days prior to the first dose of program treatment - Patients with active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years except for patients with resected melanoma, resected BCC, resected cutaneous SCC, resected melanoma in situ, resected carcinoma in situ of the cervix, and resected carcinoma in situ of the breast - Evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment / central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration - Systemic risk factor for RVO including uncontrolled glaucoma, uncontrolled hypercholesterolemia, hypertriglyceridemia or hyperglycemia - History of clinically significant cardiac dysfunction, including the following: 1. Current unstable angina. 2. Symptomatic congestive heart failure of New York Heart Association class 2 or higher. 3. History of congenital long QT syndrome or mean (average of triplicate measurements) QTcF = 450 msec at baseline; presence of clinically significant ventricular or atrial dysrhythmias = Grade 2. 4. Uncontrolled hypertension = Grade 2 (patients with a history hypertension controlled with anti-hypertensives to = Grade 1 are eligible). 5. Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower - Current severe, uncontrolled systemic disease - Major surgery or traumatic injury within 14 days prior to first dose of program treatment - History of malabsorption or other condition that would interfere with absorption of program drugs - Hypersensitivity to the active substance or to any of the excipients - Pregnant or breastfeeding women

Study Design


Intervention

Other:
Experimental combination beyond Focal Progression
Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed. Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning. Local treatment (i.e. surgery, radiotherapy).
Drug:
Pembrolizumab or Nivolumab
Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.

Locations

Country Name City State
Italy Istituto dei Tumori "Giovanni Paolo II" Bari BA
Italy ASST Papa Giovanni XXIII Bergamo BG
Italy Policlinico Sant'Orsola Malpighi Bologna BO
Italy Ospedale Policlinico San Martino Genova GE
Italy IRCCS IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Meldola FC
Italy Fondazione IRCCS Istituto Nazionale dei Tumori Milano MI
Italy Istituto Europeo di Oncologia - Divisione Melanoma, Sarcoma e Tumori Rari Milano
Italy Istituto Oncologico Veneto - IRCCS Padova PD
Italy Ospedale S. Chiara - A.O.U. Pisana Pisa PI
Italy IDI Istituto Dermopatico Immacolata Roma
Italy Istituti Fisioterapici Ospitalieri - IFO - Istituto "Regina Elena" Roma
Italy A.O.U.S. Policlinico "Le Scotte" Siena SI
Italy P.O. di Taormina - Azienda Sanitaria Provinciale di Messina Taormina ME
Italy P.O. San Lazzaro - A.O.U. Città della Salute e della Scienza di Torino - Molinette Torino TO

Sponsors (1)

Lead Sponsor Collaborator
Intergruppo Melanoma Italiano

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) time for patients with focal progression Overall survival of patients with focal progression is defined as the time, in months, from randomization to the date of death from any cause. If a patient is not known to have died, survival time will be censored at the date of last contact ("last known date alive"). Overall survival of patients with focal progression will be compared between treatment groups using a log-rank test procedure with a two-sided a =0.2 level. The OS function for each treatment group will be estimated using the Kaplan-Meier product-limit method. Median and corresponding two-sided 80% confidence intervals will be computed by treatment group. A Cox proportional hazard model for OS with treatment arm as single factor will be used to estimate the hazard ratio of vemurafenib and cobimetinib plus local treatment to Standard of Care (SOC) second-line treatment and its corresponding 80% confidence interval. From date of randomization until the date of death from any cause, assessed up to 24 months
Secondary Progression Free Survival (PFS) time for patients with focal progression PFS of patients with focal progression is defined as the time, in months, from randomization to the date of the first documented tumor progression or death due to any cause, whichever comes first. Clinical deterioration will not be considered progression. For subjects who neither progress nor die, time will be censored at the date of their last tumor assessment. For subjects who start a new anti-tumor treatment, time will be censored at the start of the new treatment. For a randomized subject who does not have any post-randomization tumor assessments and who has not died, time will be censored at the randomization date. PFS will be compared between treatment groups using a log-rank test procedure with a two-sided a =0.2 level. The PFS function for each treatment group will be estimated using the Kaplan-Meier product-limit method. Median and two-sided 80% confidence intervals (CI) for median PFS will be computed by treatment group. A Cox proportional hazard model for PFS with treatment From date of randomization until the date of death from any cause, assessed up to 24 months
Secondary Overall Survival (OS) time for patients with non-focal progression Overall survival of patients with non-focal progression is defined as the time, in months, from date of non-focal progression to first-line to the date of death from any cause. If a patient is not known to have died, survival time will be censored at the date of last contact ("last known date alive"). The OS function will be estimated using the Kaplan-Meier product-limit method. Median and corresponding two-sided 80% confidence intervals will be computed. Overall survival results of patients with non-focal progression will be descriptively compared with OS results of patients with focal progression (i.e. primary efficacy endpoint). From date of the last dose of vemurafenib and cobimetinib until the date of death from any cause, assessed up to 24 months
Secondary Comparison between Overall Survival (OS) time for patients with non-focal progression and Overall Survival (OS) results of patients with focal progression Overall survival results of patients with non-focal progression will be descriptively compared with OS results of patients with focal progression (i.e. primary efficacy endpoint). No statistical test will be foreseen for this comparison. The overall survival results are defined as the time, in months, from the date of progression to the date of death. From date of randomization or date of the last dose of vemurafenib and cobimetinib until the date of death from any cause, assessed up to 24 months
Secondary Nature of adverse events (AE) and serious adverse events (SAE) reported throughout the study Nature of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). From baseline up to 24 months after the last treatment
Secondary Frequency of adverse events (AE) and serious adverse events (SAE) reported throughout the study Frequency of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). From baseline up to 24 months after the last treatment
Secondary Severity of adverse events (AE) and serious adverse events (SAE) reported throughout the study Severity of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). From baseline up to 24 months after the last treatment
Secondary Timing of adverse events (AE) and serious adverse events (SAE) reported throughout the study Timing of adverse events (AE) and serious adverse events (SAE) verified during the study. Safety analyses will be reported by actual treatment group and on the Non-focal Progression Set. AE and SAE will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). From baseline up to 24 months after the last treatment
Secondary Changes in blood pressure Changes in blood pressure during and following vemurafenib + cobimetinib administration. Blood pressure will be measured in mmHg (millimetres of mercury). From baseline up to 24 months
Secondary Changes in heart rate Changes in heart rate during and following vemurafenib + cobimetinib administration. Heart rate will be measured in bpm (beats per minute). From baseline up to 24 months
Secondary Changes in temperature Changes in temperature during and following vemurafenib + cobimetinib administration. Temperature will be measured in °C (degrees centigrade). From baseline up to 24 months
Secondary Changes in respiratory rate Changes in respiratory rate during and following vemurafenib + cobimetinib administration. Respiratory rate will be measured in breaths per minute. From baseline up to 24 months
Secondary Changes in clinical laboratory results Changes in clinical laboratory results during and following vemurafenib + cobimetinib administration. Laboratory results will be assessed according to the Common Terminology Criteria for AEs (CTCAE version 4). From baseline up to 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04074096 - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis Phase 2
Active, not recruiting NCT05103891 - Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations Phase 1
Recruiting NCT05510895 - Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer Phase 2
Recruiting NCT05501912 - A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors Phase 1
Completed NCT03663647 - Advanced Melanoma in Russian Experience
Recruiting NCT04741997 - Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma Early Phase 1
Completed NCT04775095 - BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
Recruiting NCT05546905 - A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
Terminated NCT04190628 - Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03430947 - Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases Phase 2
Withdrawn NCT04759846 - Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma Phase 1
Recruiting NCT04911998 - A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
Not yet recruiting NCT06054191 - Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations Phase 2
Not yet recruiting NCT05275374 - XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation Phase 1/Phase 2
Completed NCT05810740 - Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations Phase 1
Recruiting NCT05800340 - Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC Phase 2
Recruiting NCT05786924 - A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Phase 1